Tyrosine Kinase Inhibitor Independent Gene Expression Signature in CML Offers New Targets for LSPC Eradication Therapy

SIMPLE SUMMARY: Chronic myeloid leukaemia (CML) is initiated by a group of cancer cells called leukaemia stem cells (LSC). These LSC can survive current tyrosine kinase inhibitor (TKI) treatments and, upon treatment withdrawal, are able to re-initiate the disease. Thus, eradicating the LSC would lik...

Descripción completa

Detalles Bibliográficos
Autores principales: Gómez-Castañeda, Eduardo, Hopcroft, Lisa E. M., Rogers, Simon, Munje, Chinmay, Bittencourt-Silvestre, Joana, Copland, Mhairi, Vetrie, David, Holyoake, Tessa, Jørgensen, Heather G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655972/
https://www.ncbi.nlm.nih.gov/pubmed/36358672
http://dx.doi.org/10.3390/cancers14215253

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655972/
https://www.ncbi.nlm.nih.gov/pubmed/36358672
http://dx.doi.org/10.3390/cancers14215253

Ejemplares similares